Statement of Changes in Beneficial Ownership (4)
02 July 2016 - 3:15AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Schechter Adam H
|
2. Issuer Name
and
Ticker or Trading Symbol
Merck & Co., Inc.
[
MRK
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
EVP & Pres-Global Human Health
|
(Last)
(First)
(Middle)
MERCK & CO., INC., 2000 GALLOPING HILL ROAD
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
7/1/2016
|
(Street)
KENILWORTH, NJ 07033
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
7/1/2016
|
|
M
|
|
50000.0000
|
A
|
$44.3000
|
50000.0000
|
D
|
|
Common Stock
|
7/1/2016
|
|
S
(1)
|
|
50000.0000
|
D
|
$57.6883
(2)
|
0.0000
|
D
|
|
Common Stock
|
|
|
|
|
|
|
|
130215.9747
(3)
|
I
|
By Trust
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (right to buy)
|
$44.3000
|
7/1/2016
|
|
M
|
|
|
50000.0000
|
2/28/2009
(4)
|
2/28/2018
|
Common Stock
|
50000.0000
|
$0.0000
|
0.0000
|
D
|
|
Explanation of Responses:
|
(
1)
|
The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
|
(
2)
|
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.4300 to $57.9400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
|
(
3)
|
Holdings include shares acquired in dividend reinvestment transactions.
|
(
4)
|
The option became exercisable in equal installments on 2/28/2009, 2/28/2010 and 2/28/2011.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Schechter Adam H
MERCK & CO., INC.
2000 GALLOPING HILL ROAD
KENILWORTH, NJ 07033
|
|
|
EVP & Pres-Global Human Health
|
|
Signatures
|
Katie Fedosz as Attorney-in-Fact for Adam H. Schechter
|
|
7/1/2016
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024